Carbinoxamine Maleate Tablet
NDC Package 73684-110-60

11-digit billing NDC: 73684011060 · Billing unit: EA · 60 EA per package
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Carbinoxamine Maleate tablets is carbinoxamine maleate is effective for the symptomatic treatment of:Seasonal and perennial allergic rhinitis.Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Dermatographism.As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.Amelioration of the severity of allergic reactions to blood or plasma. This formulation utilizes a tablet delivery system. Marketed by Blucrest Pharmaceuticals, Llc, this product is identified by NDC 73684-110 and is authorized under FDA application ANDA207484.

Identification & Billing

NDC Package Code
73684-110-60
Package Description
60 TABLET in 1 BOTTLE
Product Code
73684-110
11-Digit Billing Format
73684011060
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
60 EA
RxNorm Crosswalk
RxCUI: 1795581 - carbinoxamine maleate 6 MG Oral Tablet

Clinical Specifications

Proprietary Name
Carbinoxamine Maleate
Non-Proprietary Name
Carbinoxamine Maleate
Substance Name
Carbinoxamine Maleate
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
CARBINOXAMINE MALEATE 6 mg/1
Pharmacologic Class
Usage Information
Carbinoxamine maleate is effective for the symptomatic treatment of:Seasonal and perennial allergic rhinitis.Vasomotor rhinitis.Allergic conjunctivitis due to inhalant allergens and foods.Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.Dermatographism.As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.Amelioration of the severity of allergic reactions to blood or plasma.

Regulatory & Marketing

Labeler Name
Blucrest Pharmaceuticals, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA207484
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-16-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 73684-110-60 identifies a specific commercial package of 60 tablet in 1 bottle of Carbinoxamine Maleate, a human prescription drug labeled by Blucrest Pharmaceuticals, Llc. This product is billed for "EA" each discreet unit and contains an estimated amount of 60 billable units per package. This tablet is formulated for oral use and contains carbinoxamine maleate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Blucrest Pharmaceuticals, Llc on April 16, 2024. The current certification is valid through December 31, 2027.

How is this Blucrest Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 73684011060. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 60 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
73684-110-60
11-Digit CMS (5-4-2)
73684-0110-60

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.